Key Takeaways
- Clinical trials in Türkiye require Ethics Committee approval and authorization from the Turkish Medicines and Medical Devices Agency (TİTCK).
- The typical clinical trial start-up timeline is approximately 2–3 months, depending on study complexity.
- Türkiye offers strong patient recruitment potential for clinical trials, supported by large tertiary hospitals and experienced investigators.
- Collaborating with an experienced local CRO in Türkiye can help sponsors navigate regulatory procedures and operational requirements efficiently.
Introduction
Türkiye has become an increasingly attractive destination for global clinical trials. With its large and diverse patient population, experienced investigators, and growing research infrastructure, the country offers strong opportunities for sponsors planning to conduct clinical trials.
Pharmaceutical, biotechnology, and medical device companies evaluating global trial locations typically prioritize regulatory reliability, patient recruitment potential, and operational efficiency. Türkiye offers advantages in all three areas.
The country’s centralized healthcare system and large academic hospitals enable investigators to identify eligible patients efficiently. At the same time, the regulatory framework for clinical trials in Türkiye aligns with internationally recognized standards such as ICH Good Clinical Practice (GCP).
Sponsors planning to conduct clinical trials in Türkiye often evaluate regulatory timelines, site capabilities, and patient recruitment potential before selecting the country for global studies. This guide outlines the key steps involved in conducting clinical trials in Türkiye.
Regulatory Framework for Clinical Trials in Türkiye
Clinical trials in Türkiye are regulated by the Turkish Medicines and Medical Devices Agency (TİTCK) under the Ministry of Health.
The regulatory framework aligns with international clinical research standards, including:
- ICH Good Clinical Practice (ICH-GCP)
- European clinical research guidelines
- National clinical trial regulations issued by TİTCK
These regulations ensure the ethical conduct of clinical research, protection of study participants, and reliability of clinical data generated in Türkiye.
Before initiating a study, sponsors must ensure that the clinical trial protocol, investigator qualifications, and regulatory documentation comply with national regulatory requirements.
Clinical Trial Approval Process in Türkiye
To initiate a clinical trial in Türkiye, sponsors must follow a structured regulatory pathway:
Protocol Development
↓
Ethics Committee Submission
↓
Ethics Committee Approval
↓
Regulatory Submission to TİTCK
↓
Regulatory Authorization
↓
Site Initiation
↓
Patient Recruitment
Both Ethics Committee approval and regulatory authorization from TİTCK are required before patient enrollment can begin.
Ethics Committee Approval in Türkiye
Ethics committees play a critical role in protecting the rights and safety of clinical trial participants.
Before submitting an application to the regulatory authority, sponsors must obtain approval from an authorized Ethics Committee.
The committee typically reviews:
- Clinical trial protocol
- Investigator brochure
- Informed consent forms
- Investigator CVs
- Insurance documentation
Ethics committees ensure that the study design is ethically appropriate and scientifically justified.
Regulatory Authorization from TİTCK
Following ethics committee approval, the clinical trial application must be submitted to TİTCK for regulatory review.
The submission package generally includes:
- Final clinical trial protocol
- Investigator brochure
- Ethics committee approval documentation
- Informed consent forms
- Investigator and site information
- Insurance documentation
- Investigational product information
Clinical trials may only begin after both ethics committee approval and regulatory authorization from TİTCK have been granted.
Clinical Trial Start-Up Timeline
Study start-up timelines are an important factor for sponsors planning international clinical development programs.
Typical timelines in Türkiye include:
| Clinical Trial Start-Up Step | Typical Timeline in Türkiye |
| Ethics Committee Review | 4–8 weeks |
| TİTCK Regulatory Review | 4–8 weeks |
| Site Initiation | 2–4 weeks |
In many cases, clinical trials in Türkiye can begin within two to three months, depending on study complexity and documentation readiness.
Patient Recruitment Advantages in Türkiye
Patient recruitment is one of the most significant challenges in global clinical development. Türkiye offers several advantages in this area.
The country’s high-volume hospitals and centralized healthcare system enable investigators to identify eligible patients efficiently.
Strong recruitment performance has been observed in therapeutic areas such as:
- Oncology
- Rare diseases
- Cardiovascular diseases
- Metabolic disorders
These factors make Türkiye an attractive location for global clinical trialss.
Operational Considerations for Sponsors
Sponsors conducting clinical trials in Türkiye must also consider several operational factors, including:
- Importation procedures for investigational medicinal products
- Translation of study documentation into Turkish
- Insurance requirements for clinical trial participants
- Site contract negotiations
- Compliance with KVKK, Türkiye’s personal data protection law
Careful planning of these operational aspects helps ensure smooth study execution and regulatory compliance.
The Role of Local CRO Partners
Many international sponsors collaborate with local Contract Research Organizations (CROs) when conducting clinical trials in Türkiye.
Local CRO partners provide valuable support with:
- Regulatory submissions and authority communication
- Ethics committee coordination
- Site feasibility and investigator selection
- Clinical monitoring and project management
- Pharmacovigilance and safety reporting
Medex CRO is an experienced clinical research organization in Türkiye, supporting international sponsors with regulatory submissions, feasibility assessments, clinical monitoring, pharmacovigilance, and full clinical trial management.
Conclusion
Türkiye offers global sponsors a strong environment for clinical research, combining experienced investigators, reliable patient recruitment potential, and internationally aligned regulatory standards.
With appropriate regulatory planning and collaboration with experienced local partners, sponsors can efficiently conduct high-quality clinical trials in Türkiye.
As global clinical development programs continue to expand, Türkiye is expected to remain an important destination for international clinical research.
Planning a Clinical Trial in Türkiye?
If your organization is considering conducting clinical trials in Türkiye, working with an experienced local partner can significantly streamline the regulatory and operational process.
Medex CRO supports global sponsors throughout the entire clinical trial lifecycle, including:
- Regulatory submissions and TİTCK communication
- Ethics committee coordination
- Site feasibility and selection
- Clinical monitoring
- Pharmacovigilance
- Data management and project management
📩 Contact Medex CRO to discuss your upcoming clinical trial in Türkiye.
FAQ
How long does it take to start a clinical trial in Türkiye?
Clinical trial start-up typically takes 2–3 months, including ethics committee review and regulatory authorization from TİTCK.
Who regulates clinical trials in Türkiye?
Clinical trials are regulated by the Turkish Medicines and Medical Devices Agency (TİTCK) under the Ministry of Health.
Are clinical trial data generated in Türkiye internationally accepted?
Yes. Clinical trials conducted in accordance with ICH Good Clinical Practice (GCP) standards are generally accepted by international regulatory authorities.
Why work with a local CRO in Türkiye?
Local CROs provide regulatory expertise, site access, and operational support, helping sponsors conduct clinical trials efficiently.
Can foreign sponsors conduct clinical trials in Türkiye?
Yes. International pharmaceutical, biotechnology, and medical device companies can conduct clinical trials in Türkiye, provided that studies receive approval from an authorized Ethics Committee and regulatory authorization from TİTCK.
Why is Türkiye attractive for clinical trials?
Türkiye offers a large patient population, experienced investigators, high-volume hospitals, and a regulatory framework aligned with international standards such as ICH-GCP.
Official sources include:
European Medicines Agency (EMA). Clinical Trials in Human Medicines
https://www.ema.europa.eu
International Council for Harmonisation (ICH). Good Clinical Practice Guidelines
https://www.ich.org
Republic of Türkiye Ministry of Health – Turkish Medicines and Medical Devices Agency (TİTCK)
https://titck.gov.tr
U.S. National Library of Medicine. ClinicalTrials.gov
https://clinicaltrials.gov
World Health Organization. International Clinical Trials Registry Platform
https://www.who.int/clinical-trials-registry-platform
Bir yanıt yazın